193 related articles for article (PubMed ID: 25182707)
1. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
Zheng YB; Zhan MX; Zhao W; Liu B; Huang JW; He X; Fu SR; Zhao Y; Li Y; Hu BS; Lu LG
Med Oncol; 2014 Oct; 31(10):209. PubMed ID: 25182707
[TBL] [Abstract][Full Text] [Related]
2. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma.
Zheng YB; Huang JW; Zhan MX; Zhao W; Liu B; He X; Li Y; Hu BS; Lu LG
Tumour Biol; 2014 Nov; 35(11):11473-81. PubMed ID: 25123269
[TBL] [Abstract][Full Text] [Related]
4. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Destro A; Ligorio C; Tronconi MC; Bozzarelli S; Carnaghi C; Di Tommaso L; Giordano L; Roncalli M; Santoro A
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1179-87. PubMed ID: 23568548
[TBL] [Abstract][Full Text] [Related]
7. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
8. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
[TBL] [Abstract][Full Text] [Related]
9. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
da Fonseca LG; Barroso-Sousa R; Bento Ada S; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
Med Oncol; 2014 Nov; 31(11):264. PubMed ID: 25273866
[TBL] [Abstract][Full Text] [Related]
11. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
Zheng YB; Zhao W; Liu B; Lu LG; He X; Huang JW; Li Y; Hu BS
Asian Pac J Cancer Prev; 2013; 14(9):5527-31. PubMed ID: 24175853
[TBL] [Abstract][Full Text] [Related]
12. The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
Shao YY; Chang YL; Huang CY; Hsu CH; Cheng AL
Oncology; 2013; 85(5):312-6. PubMed ID: 24217400
[TBL] [Abstract][Full Text] [Related]
13. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Kim HY; Lee DH; Lee JH; Cho YY; Cho EJ; Yu SJ; Kim YJ; Yoon JH
BMC Cancer; 2018 Mar; 18(1):307. PubMed ID: 29558905
[TBL] [Abstract][Full Text] [Related]
14. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
15. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
[TBL] [Abstract][Full Text] [Related]
16. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
[TBL] [Abstract][Full Text] [Related]
18. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
20. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]